Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APO866 in Refractory or Relapsed Cutaneous T-cell Lymphoma
NCT00431912Phase 2Completed
- Sponsor
- Valerio Therapeutics
- Start
- Feb 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of daporinad in cutaneous T-cell lymphoma (CTCL), sponsored by Valerio Therapeutics. Primary endpoint: Objective Response Rate at 16 weeks. Started Feb 2007; status: completed.
02
Drugs
daporinad
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00431912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431912.